Request Trial
celgene-logo
Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)
31 July 2015Americas

Celgene calls for Kyle Bass sanctions

Pharmaceutical company Celgene has requested that the US Patent and Trademark Office (USPTO) sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review (IPR) petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J unit targets former employee over alleged mass data theft
17 March 2026   Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.
Americas
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
12 March 2026   The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.
Americas
Astellas blocks generic version of key urology drug until 2030
12 March 2026   The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

US firm boosts patent bench with Desmarais hire
J&J unit targets former employee over alleged mass data theft
HSF Kramer hires patent litigator as partner in Germany
INTA: ‘New normal’ for in-house counsel as budgets fall
Mylan withdraws defence claims against Novo in Wegovy dispute
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
Astellas blocks generic version of key urology drug until 2030
Orrick adds specialist licensing partner in Silicon Valley